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Mutations in AIPL1 are associated with Leber Congenital Amaurosis (LCA), a major cause of childhood blindness, yet the cellular
function of the encoded protein has yet to be fully elucidated. In order to investigate the biochemistry of AIPL1, we have developed a
system for the expression of the recombinant protein in bacteria and its subsequent purification. The secondary structure and
thermostability of wild-type and mutant proteins have been examined by circular dichroism (CD) spectroscopy. Some of the variants,
notably W278X and P376S, had markedly different secondary structure compositions, indicating that the proteins had not folded properly,
whilst W278X and T114I were particularly thermolabile. When eukaryotic cells were transfected with the AIPL1 expression constructs,
we show by immunofluorescence microscopy that wild-type protein is distributed throughout the nucleus and cytoplasm. Several of the
mutants give similar results. With two of the disease-associated variants (W278X and A336D2), however, the protein remains in the
cytoplasm in aggresome-like particles. These particles were shown to be ubiquitinated, indicating that the mutant protein had been tagged
for proteosomal degradation. On this basis, we can conclude that wild-type protein is expressed in a soluble and folded manner, and that
some of the disease-associated mutant proteins are nonfunctional because they are insoluble and are degraded by the cell. Other mutations
appear to have a more localised effect on secondary structure, which does not result in insolubility or affect protein targeting, but reduces
the stability of the protein at human body temperature.
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Mutations in AIPL1, the aryl-hydrocarbon interacting
protein-like 1 gene, have been linked to the autosomal
recessive eye disease, Leber Congenital Amaurosis (LCA,
OMIM no. 20400) [1]. LCA is the most severe form of
inherited blindness in children and accounts for approx-
imately 5% of all inherited retinal disease [2]. To date, six
genes have been associated with LCA, GUCY2D, CRX,
RPE65, CRB1, RPGRIP and AIPL1. Mutations in AIPL1
are believed to account for around 10% of all cases ofta 1690 (2004) 141–149
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dystrophy (CORD) [3].
Expression of the AIPL1 protein appears to be restricted
to photoreceptor cells and pinealocytes [1]. However, the
functional role of AIPL1 remains unknown. The protein was
named AIPL1 due to its similarity (49% identity) to human
aryl hydrocarbon receptor-interacting protein (AIP, also
called ARA9 and XAP2) [6]. Like AIP, it contains three
tetratricopeptide (TPR) repeat motifs, 34 amino acids in
length, that are thought to serve as interfaces for protein–
protein interactions and are commonly found in proteins with
nuclear transport or protein chaperone activity [7]. It also
contains an N-terminal domain with similarity to that found
in several immunophilin proteins and shown in the latter to
have peptidyl-prolyl isomerase activity [6]. In contrast to
AIP, however, human AIPL1 contains a proline-rich domain
at its C-terminus. Poly-proline sequences are found in
proteins involved in the rapid recruitment or interchange of
proteins, such as in some signalling cascades or in initiators
of transcription [8]. The possession of this proline-rich tail
appears to be restricted to AIPL1 in primates [4].
Screening of the AIPL1 gene in a panel of patients with a
range of retinal degenerative diseases has, to date, revealed a
total of 19 different changes, including amino acid sub-
stitutions, premature stops, deletions, insertions, frame-shifts
and one splice site mutation [3]. In all the fully characterised
LCA families, these were found as homozygous or
compound heterozygous changes, consistent with the reces-
sive nature of the disease. A single mutation (P351D12),
present in a heterozygous proband, was also identified in two
CORD families. Four related LCA families carrying a
homozygous W278X mutation are reported to also have
bilateral keratoconus, an anterior segment abnormality,
which may be linked to the AIPL1 mutation [1,9].
By screening AIPL1 against a bovine retinal cDNA in a
yeast two-hybrid system, a potential AIPL1-interacting
protein has been identified [10]. This protein, NUB1
(NEDD8 ultimate buster 1), is a regulator of NEDD8
expression and is thought to play an important role in the
regulation of the cell cycle. It has been hypothesised that
AIPL1 plays a role in the cytosolic stability and/or nuclear
transport of NUB1 during photoreceptor development [10].
In mouse, the AIPL1 protein has been detected in the inner
segments of photoreceptors [1], whereas a more detailed
analysis of human retina demonstrated that it is the rod cells
that appear to harbour AIPL1 [11]. Recently, on the basis of a
more extensive yeast 2-hybrid screen, AIPL1 has been
implicated in the process of farnesylation [12].
In this study, we describe an expression system for the
production of folded, soluble recombinant AIPL1, which
has enabled an initial characterisation of the protein to be
undertaken. Using the same expression system, we have
determined the subcellular localisation of the human protein
when expressed in recombinant form in mammalian cells.
In addition, we have studied the effect on localisation of
some of the disease-causing substitutions linked to LCAand CORD in order to gain some insight into their
underlying pathology.2. Experimental procedures
2.1. Cloning of AIPL1 into His-tagged expression vector
and generation of mutants
The complete cDNA sequence for human AIPL1 was
amplified from retinal cDNA as an NcoI–SalI fragment
using endonuclease-tagged 5V- and 3V-AIPL1 primers and
Pfu DNA polymerase. This was cloned first into the TA-
cloning vector, pGEM-Teasy (Promega), and then trans-
ferred into the vector pTriEx-1 (Novagen) via the NcoI and
SalI sites. Sequencing confirmed that the resulting clone,
pTriEx.AIPL1His, contained the complete AIPL1 sequence
in frame and with an additional 10-codon C-terminal His-
tag extension.
Constructs containing mutations encoding single amino
acid substitutions and the L169L substitution at nucleotide
509 were generated with the assistance of a GeneEditor
site-directed mutagenesis kit (Promega) using the pGEM-
Teasy construct and appropriate mutagenesis primers. The
W278X and S328X mutant constructs were generated as
described above for the wild-type construct but using the
5V-AIPL1 primer and a SalI-tagged W278X or S328X
primer. This resulted in either codon W278 or S328 being
replaced by the 10-codon C-terminal His-tag extension. A
PCR approach was used to generate the P351D12 construct
and a combination of PCR and mutagenesis was used to
make the A336D2 variant. All constructs were verified by
sequencing. Details of all primers used and cloning
strategies can be obtained on application to the correspond-
ing author.
2.2. Expression of AIPL1 in E. coli and purification of the
protein
Transformation of pTriEx.AIPL1His into E. coli strain
BL21(DE3) pLysS allowed AIPL1 to be overproduced as a
His-tagged protein. The transformed strain was grown at 37
8C in LB supplemented with chloramphenicol, ampicillin
and 1% glucose. The cells were induced with 0.4 mM IPTG
as soon as the culture reached an OD600 of 0.6 and the cells
were then left to grow overnight at room temperature. After
harvesting the cells by centrifugation, the cells were lysed
by sonication, centrifuged and the supernatant applied to a
His.Bind (Novagen) column charged with NiSO4. The
purification was performed according to the manufacturer’s
instructions. The protein was further purified by gel
filtration on a Sephadex G75 column (130 cm) attached
to an Akta protein purification system. The column was run
in 50 mM Tris–HCl, pH 8.0, with 200 mM NaCl and 10
mM h-mercaptoethanol. The AIPL1-containing fractions
were detected by SDS-PAGE.
Fig. 1. SDS-PAGE analysis of wild-type AIPL1 purified by metal chelate
chromatography. Lane 1: Molecular mass markers as shown (kDa). Lane 2:
Protein purified from E. coli cells containing an expression plasmid
harbouring wild-type AIPL1 cDNA. The protein purifies with the truncated
form of AIPL1 around 30 kDa. Purification of AIPL1 from E. coli cells
containing an expression plasmid harbouring AIPL1 with an alternative
leucine codon at position 169 (L169L) does not produce this contaminant.
(For color see online version).
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HEK 293T cells were transfected with wild-type or
mutant pTriEx.AIPL1His using GeneJuice (Novagen) and
cultured for 48 h. Cells were washed twice with PBS and
harvested by scraping. Cell pellets were washed twice
more with PBS and then stored at 20 8C. Cell pellets
were resuspended in 300-Al lysis buffer (20 mM HEPES
pH 7.9, 450 mM NaCl, 4.5 mM MgCl2, 0.5 mM DTT, 0.5
mM PMSF, 0.25 mM benzamidine, 0.2% Nonidet P-40)
per 90-mm dish of cells. Aliquots of these whole cell
extracts (WCE) were kept and the remainder centrifuged at
18,500g for 15 min at 4 8C. The supernatant containing
the soluble protein fraction was retained. Protein concen-
trations of all extracts were determined using a BioRad
protein assay kit with BSA as a standard.
2.4. Western blot analysis of protein extracts
Aliquots containing equal amounts of total proteins were
separated by SDS-PAGE (12%) and transferred to ZetaP-
robe membranes (Gibco) using standard protocols. Mem-
branes were blocked with 5% nonfat dry milk in PBS and
incubated with a-His.tag monoclonal antibody (Novagen)
(100 ng/ml). After washing, the blot was probed with a
horseradish peroxidase (HRP)-conjugated a-mouse anti-
body (Pierce, UK) (80 ng/ml). Immunoreactive protein was
detected using enhanced chemiluminescence (National
Diagnostics).
2.5. Immunofluorescence analysis of transfected COS7 cells
by confocal microscopy
COS7 cells were plated on to glass coverslips and
transfected with wild-type or mutant pTriEx.AIPL1His
plasmid DNA using GeneJuice transfection reagent (Nova-
gen). Transfection was performed in the presence of serum
but in the absence of antibiotics. Cells were cultured for 48
h without further changes of the culture medium. After
washing with PBS, cells were fixed with 4% paraformal-
dehyde, permeabilised with 0.1% Triton X-100 and
blocked with 5% fetal calf serum. Cells were then
incubated with a-His.Tag monoclonal antibody (Novagen)
(100 ng/ml). After repeated washing with PBS, cells were
blocked with 5% goat serum and then incubated with an
FITC-conjugated a-mouse antibody (Jackson ImmunoR-
esearch Laboratories) (30 Ag/ml). Cells transfected with the
wild-type and mutant constructs W278X and A336D2 only
were co-probed with a rabbit a-ubiquitin polyclonal
antibody (Neomarkers) (1:100) followed by a TRITC-
conjugated a-rabbit secondary antibody (Jackson Immu-
noResearch Laboratories) (15 Ag/ml). After washing, cells
were mounted in Vectashield mounting medium containing
DAPI (1.5 Ag/ml) (Vector Laboratories Inc.). Cells were
viewed using a Zeiss LSM510 confocal fluorescent
microscope.2.6. Circular dichroism (CD) spectra
Purified AIPL1 (N95% purity) was dialysed against 5
mM sodium phosphate, 0.1 mM DTT, pH 7.9 and
concentrated in a Vivaspin 6 ml concentrator (VivaScience).
CD spectra were recorded at 25 8C on ~0.1 mg/ml samples
of AIPL1 in a 1-mm quartz cuvette (Hellma) using an Aviv
62DS Spectrometer, with data acquired between 180 and
260 nm at 0.5-nm intervals.
The thermal stability of wild-type and mutant AIPL1
proteins was followed by monitoring the CD spectrum
(185–260 nm) of the protein solution (~0.1 mg/ml) on an
Aviv 62DS spectrometer fitted with a peltier temperature
controller. Measurements were taken over the range 20–62
8C at 3 8C intervals. Protein samples were equilibrated at
each temperature for 3 min prior to spectra acquisition.3. Results
3.1. Expression and purification of wild-type recombinant
AIPL1 from E. coli
The complete cDNA sequence of human AIPL1 was
cloned into the expression vector pTriEx, generating a C-
terminal His-tagged AIPL1 fusion containing 10 extra amino
acids (-VEHHHHHHHH*). When transformed into E. coli,
this plasmid allowed the expression of recombinant AIPL1
after induction with IPTG. A comparison of crude cell
lysates of induced versus noninduced expression by SDS/
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ing to the expected size of the recombinant AIPL1. However,
a minor band at 30 kDa was also consistently seen (Fig. 1).
Passage of the lysate from the induced cells through a His-
bind purification column and elution with imidazole resulted
in the isolation of a 45- and a 30-kDa protein from the
cellular extract. Both proteins cross-reacted with antibodies
raised against the poly-His tag, indicating that both proteins
contained the poly-histidine motif, thereby suggesting that
the 30-kDa form may represent a truncated version of
AIPL1. N-terminal sequencing of the 45-kDa protein gave a
sequence that corresponded to the predicted gene-derived N-
terminus of the protein. N-terminal sequencing of the 30-kDa
protein gave a sequence corresponding to amino acids 170–
175 of AIPL1. Expression of AIPL1 from the same pTriEx
construct in a human cell line gave only the 45-kDa protein
(data not shown).
Truncated proteins from recombinant systems often
arise from proteolytic breakdown of the protein. However,Fig. 2. AIPL1 mutations selected for this study. (A) Type of mutation and dise
mutations. The three TPR domains correspond to residues 118–151, 202–237 and
*All mutations cause LCA except P351D12 (starred), which causes a cone-rod din the case of AIPL1, it was noticed that a leucine codon
at position 169 of AIPL1, facilitated by a good potential
ribosome binding site located 8 base pairs upstream of
this codon, could serve as an alternative translation start
codon in a prokaryotic system. Thus, both the 45-kDa
and the 30-kDa proteins may be expressed in E. coli
depending on which of the two translational start sites is
used. Indeed, when this leucine codon (CTG) in the
AIPL1 cDNA was mutated to an alternative leucine
codon (CTT) (L169L), only the 45-kDa protein was
produced, with no 30-kDa truncated protein detected
(Data not shown).
The 45-kDa AIPL1 protein was purified to homogeneity
from soluble protein extracts of E. coli cells expressing
wild-type AIPL1 from the modified L169L construct. The
purification was achieved by passage of the cell extract
through a His.bind column followed by high-resolution gel
filtration chromatography. The protein eluted from the gel
filtration column at a point that corresponded to aase phenotype. (B) Domain structure of AIPL1 showing locations of the
264–297 and the proline-rich C-terminal region extends from residue 329.
ystrophy.
Fig. 3. CD analysis and melting profile of purified AIPL1. Far-UV CD
spectrum of purified wild-type AIPL1. Purified AIPL1 (0.2 mg/ml) was
subject to CD spectrometry over the range 180–260 nm. The spectrum
shows an average of five scans and is consistent with a protein containing a
mixed a/h structure. Deconvolution of this data suggests that the protein
contains 40% helix and 17% h-strand.
Table 1
Structural analysis of wild-type and mutant proteins from CD spectra
Averages
Protein Helix Strand Turns Unordered Tm (8C)
WT 47.1 10.3 18.1 25.0 44.1
T114I 47% 16% 18% 20% 34.8
A197P ND 40.5
I206N 40.4 16.1 17.7 26.1 41.4
C239R ND 46.7
G262S ND 40.1
W278X 28% 23% 20% 27% 33.2
R302L 42% 15% 20% 25% 43.2
P351D12 45.0 13.1 17.7 24.9 38.7
P376S 33% 19% 21% 26% 43.4
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exists as a monomer.
3.2. Expression of mutant variants of AIPL1 in E. coli
Of the 19 recessive mutations that have now been
reported [1,3,9], 11 were selected for study and one further
artificial variant missing the proline tail was constructed;
the list of selected mutations and their positions within the
protein domains are shown in Fig. 2. The location of these
mutations within the different domains of AIPL1 is shown
in Fig. 2b. An important prerequisite to a study of mutant
forms of AIPL1 is to establish whether the mutant proteins
can be expressed in E. coli and recovered in soluble form.
To explore this further, the mutations listed in Fig. 2,
which include those causing CORD and LCA, were
generated by site-directed mutagenesis. All constructs also
had the modified L169L codon to eliminate this codon as a
start point for translation. Extracts from bacterial cells
producing wild type and these mutant proteins were
subjected to Western blot analysis using an anti-His.tag
antibody to probe for the presence of His-tagged AIPL1
protein (data not shown). In summary, it was found that,
when expressed in E. coli, all the mutant variants were
produced in detectable quantities, although there was some
variation in the ratio of soluble to insoluble protein.
3.3. CD analysis of purified AIPL1 proteins
CD spectrometry was used to determine whether the
recombinant proteins were correctly folded. Highly purified
AIPL1 was equilibrated into a low salt buffer suitable for
CD analysis. The spectrum shown in Fig. 3 of the wild-type
protein is the smoothed average of five scans with baselinecorrection for solution contributions. The secondary struc-
tural content was assessed using CDSSTR, Selcon 3 and
Contin [13] programs on the Dichroweb Webserver [14,15].
This analysis indicated that wild-type AIPL1 has approx-
imately 47% helix and 10% h-strand. The secondary
structures of AIPL1 predicted by a wide range of computer
programs all show a mixed a/h arrangement of structural
elements. The prediction of GOR-IV developed by Garnier
et al. [16], a method based on information theory, provides a
reasonable agreement with the experimentally derived data
(40% helix and 15% h-strand).
Although the wild-type recombinant protein appears to
have a high degree of secondary structure at 25 8C, it is very
sensitive to thermal denaturation. When the CD spectrum of
AIPL1 was examined over a range of temperatures, the
protein was found to have a midpoint of unfolding around
44 8C, assuming a two-state model (i.e., that the unfolding
transition proceeds with no long-lived intermediates).
A number of the mutant proteins were selected for
structural studies and the results are presented in Table 1.
Deconvolution of the CD spectra revealed that all but two
of these variants have a similar secondary structure
content to the wild-type protein. The exceptions are
W278X and P376S, both of which had significantly
reduced helical content. Helical content is the most
reliable secondary structure element measured by CD
and the large reduction in helical content of the W278X
and P376S variants would suggest that these proteins
have folded in significantly different topologies to that of
the wild-type protein.
The thermal stability of the mutant variants was also
monitored by CD (Table 1). Notably, the T114I and
W278X variants displayed greatly reduced midpoint
unfolding temperatures in comparison to the wild-type
protein, indicating that these two variants were much less
stable.
3.4. Intracellular localisation of wild-type AIPL1 expressed
in mammalian cells
The pTriEx-based wild-type AIPL1 expression construct
was used to transfect COS7 cells and the location of the
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microscopy (Fig. 4A-1). For detection, a primary antibody
against the His-tag was used together with a FITC-
conjugated secondary antibody. The expressed AIPL1
protein appears as a green signal (middle panel). The
nucleic acids in the cells were counterstained with DAPI to
give a blue signal which clearly delineates the nuclei (left
panel). By merging the two separate DAPI and FITC
images, the co-localisation of the AIPL1 and nucleic acid
signals is revealed.
The wild-type AIPL1 gives a signal throughout the
cytoplasm and nucleus but is excluded from the nucleoli
(Fig. 4A-1). The absence of signal in cells transfected with
empty pTriEx vector (Fig. 4A-2) confirms that the greenFig. 4. Confocal immunofluorescent images showing cellular localisation of wild-
with pTriEx.AIPL1His were cultured for 48 h and then processed for immunofluo
antibody (green). Nuclei were counterstained with DAPI (blue). (A-1) Cells tran
throughout the cytoplasm and in the nucleus but excluded from the more densely s
no green signal. (B-1,2) Cells transfected with mutant constructs I206N and A351
mutant constructs W278X and A336D2 show the presence of perinuclear inclusi
mutant AIPL1 in these inclusion bodies is ubiquitinated (red). No ubiquitin signal wsignal arises from the presence of AIPL1 rather than some
endogenous histidine-rich protein in the cells.
3.5. Mislocalisation of mutant AIPL1 proteins linked to LCA
In order to study the cellular pathology of disease-
causing substitutions in AIPL1, a number of mutations
linked to LCA and CORD were selected for further study
in eukaryotic cells (see Fig. 2). Mutations T114I, I206N,
R302L, P351D12 and P376S resulted in cellular local-
isation that was very similar to wild type (examples are
shown in Fig. 4B-1,2). Failure of mutations P351D12 and
P376S to affect localisation suggests that the proline-rich
C-terminal domain is not directly involved in translocationtype and mutant AIPL1 proteins expressed in COS7 cells. Cells transfected
rescence using a-His.tag antibody followed by FITC-conjugated secondary
sfected with WT AIPL1 construct showing the presence of AIPL1 (green)
tained (blue) nucleoli. (A-2) Cells transfected with empty pTriEx vector give
D12 have a similar appearance to wild type. (B-3,4) Cells transfected with
on bodies (green). Probing with an anti-ubiquitin antibody reveals that the
as seen from cells transfected with the wild-type construct. Bar size, 20 Am.
V.A. Gallon et al. / Biochimica et Biophysica Acta 1690 (2004) 141–149 147to the nucleus. This was confirmed by the transportation to
the nucleus of the S328X mutant, in which the proline-rich
region of AIPL1 is removed completely (result not shown).
In contrast, two of the mutations studied, W278X and
A336D2, had a drastic effect on localisation with the signal
confined to densely staining inclusion bodies around the
nuclei (Fig. 4B-3,4), leading to distortion of the nucleus.
Probing of these transfected cells with an anti-ubiquitin
antibody revealed signals that co-localised with the
perinuclear inclusions, indicating that the protein was
ubiquitinated.
The localisation results suggested that the W278X and
A336D2 variants produced insoluble protein. To verify this,
Western blot analysis was also performed on protein
extracts from HEK 293T cells transfected with the wild-
type and mutant constructs (Fig. 5). We used 293T cells
rather than COS7 cells since transfection levels are higher in
this line, resulting in a higher level of AIPL1 expression.
They could not be used, however, for the immunofluor-
escence microscopy as they adhere only poorly to glass
coverslips. Whole cell extracts and the soluble protein
fractions from transfected 293T cells were analysed by
SDS-PAGE. Immunoprobing using the a-His.tag antibody
revealed strong expression of the WT protein, the majority
being soluble. Mutants R302L and P351D12 (data not
shown) gave a similar result, whereas W278X and A336D2
failed to give a band from the soluble fraction and the total
amount of AIPL1 protein present in the cell extracts was
much lower than with wild type.Fig. 5. Coomassie-stained SDS-PAGE gel and Western blot analysis of protein ex
Aliquots of whole cell extracts and soluble protein extracts containing equal amou
AIPL1 and mutant R302L were strongly expressed and the majority of the protein
protein.4. Discussion
In this paper, we describe the expression, purification and
characterisation of the human AIPL1 protein. Expression of
human wild-type cDNA for AIPL1 in E. coli results in the
production of two proteins, one of 30 kDa and the other of
the expected molecular mass of 45 kDa. The presence of the
30-kDa protein would appear to be an artefact caused by the
presence of an alternative translational start site on the
mRNA, and represents an unforeseen hazard of producing a
eukaryotic protein in a prokaryotic host. Site-directed
mutagenesis of this site overcame the problem. We have
also been able to express a range of mutant forms of AIPL1
as recombinant proteins in E. coli.
CD spectroscopy was used to investigate the secondary
structure of AIPL1 and its mutant variants, as well as its
thermostability. Deconvolution of the CD spectra of wild-
type AIPL1 revealed that the protein possesses consid-
erable secondary structure including over 40% helix,
which agrees with secondary structure prediction algo-
rithms. Of interest was the finding that the disease-causing
variants, W278X and P376S, have a significantly different
secondary structure composition in comparison to wild-
type protein. These substitutions lead to a large drop in
the level of a-helix within the protein, suggesting that the
protein has not folded correctly. The early termination of
the W278X protein is likely to produce a variant with a
less well ordered topology and, as outlined below, this
mutant also tends to form aggregates when expressed intracts from 293T cells transfected with WT and mutant AIPL1 constructs.
nts of total proteins were analysed as described under Section 2. Wild-type
was soluble, but mutants W278X and P336D2 failed to express any soluble
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acid proline at position 376 is also likely to have a
serious effect on structure since proline’s cyclic five-
membered ring imposes rigid constraints on rotation in the
peptide backbone.
AIPL1 was found to have a midpoint unfolding temper-
ature of 44 8C. This is significant since mutations introduced
into proteins tend to make them more unstable and, as the
midpoint unfolding temperature for AIPL1 is close to the
body temperature of 37 8C, mutations in AIPL1 might be
expected to have a significant effect on protein stability in
vivo. Indeed, measurement of the midpoint unfolding
temperatures of the protein variants T114I and W278X
shows that they are significantly reduced from that observed
for the wild-type protein (Fig. 2). These two variants have a
midpoint unfolding temperature that is 10 8C lower than that
of the wild-type protein. The aliphatic substitution of a
isoleucine for the polar threonine residue could easily
destabilise the protein through the loss of hydrogen bonding
capacity whereas the CD analysis of W278X has shown that
the protein has a significantly different secondary structure.
The variant P351D2 also has a reduced midpoint unfolding
temperature, which is close to the normal human body
temperature, suggesting that thermal stability may be a
problem in this variant also.
When transfected into mammalian cells, the subcellular
localisation of AIPL1 is similar to that for AIP in that it is
found localised in the cytoplasm and nucleus but not in the
nucleolus. From this, we infer that AIPL1 may be involved
in an analogous communication process between the
cytoplasm and the nucleus. AIP is known to be involved
in the dioxin-signalling pathway [17] and forms a cytosolic
complex with the aryl hydrocarbon receptor (AHR) and heat
shock protein 90 (hsp90). The cellular localisation of AIPL1
reported here and the sequence similarity with AIP strongly
support an analogous role for AIPL1 in the regulation of
ligand–receptor signalling. Initially, it was shown that
AIPL1 interacts with the cell cycle regulator protein
NUB1 [10] and it has been proposed that AIPL1 is essential
for the normal development of both rod and cone cells [18].
In addition, a role in farnesylation has been suggested since
AIPL1 was found not only to interact with farnesylated
proteins but also to enhance the processing of farnesylated
proteins [12].
A study of the subcellular localisation of a number of
mutant variants of AIPL1 revealed that although some
mutants show a similar distribution to wild-type protein, the
W278X and A336D2 mutants both failed to translocate into
the nucleus and resulted in the accumulation of ubiquiti-
nated protein in perinuclear inclusion bodies. Consistent
with this finding is the observation that for both mutants, no
soluble protein was present in the transfected cells. This
reduction in soluble protein level is unlikely to be due to a
difference in transfection efficiency and suggests that
mutants W278X and A336D2 are less stable than wild-type
AIPL1. Furthermore, the absence of any soluble proteinsuggests that the cytoplasmic signals seen through the
fluorescence microscope originated from insoluble protein
aggregates. Both these variants would be predicted to have a
serious effect on protein structure as W278X results in a
protein truncated in the middle of TPR3 and A336D2 results
in an altered and extended C-terminus which contains
additional basic residues that contribute to raising the
predicted pI of the protein from 6.31 (wild type) to 8.03.
Similar perinuclear inclusions to those described above have
been described by Johnson et al. [19] in cystic fibrosis
transmembrane conductance regulator (CFTR) patients, and
termed them aggresomes and showed that they arise from
misfolded, ubiquitinated protein. It is possible that over
time, similar aggresomes accumulate in the photoreceptors
of LCA patients carrying these two mutations and that this
accumulation triggers apoptosis. Conversely, the pathology
may simply arise from an absence or insufficiency of
functional AIPL1 protein.
Out of the 11 protein variants of AIPL1 studied in this
report, we have produced evidence that five of these are due
to the effect the mutation has on protein structure, stability or
transport. W278X has an altered secondary structure, a
lowered midpoint unfolding temperature and forms insoluble
aggresomes when produced in human cells. The A336D2
variant was not stable enough for analysis by CD, but also
formed similar aggresome-like particles when produced in
eukaryotic cells. T114I is a heat-sensitive variant with a
melting temperature of 34 8C, and so is likely to denature at
normal body temperatures. To a lesser extent, the same
argument can be applied to the P351D12 variant, which has a
midpoint unfolding temperature of 38 8C. P376S has a
significantly altered secondary structure when compared to
wild-type protein and, although it is transported normally
within the cell, it is likely that the change in secondary
structure and the subsequent effect on tertiary structure do not
allow the protein to interact with its cognate partners.
It has been suggested that the R303L variant is not
disease related since the mutant protein interacted with
farnesylated proteins in a similar way to wild-type protein.
However, an earlier report demonstrated that this mutation
did interfere with the interaction between AIPL1 and
NUB1 [10]. The NUB1 binding site is thought to be at the
C-terminus of AIPL1 and the R302L substitution, being at
the C-terminus, may have a direct effect on binding to
NUB1. Our findings reveal that the R302L variant folds
like wild type and locates like wild type when expressed
in transfected cells, but do not tell us whether the mutation
is disease-causing. The other AIPL1 variants also appear
to have little effect on overall secondary structure and
protein translocation, suggesting that their effect may be
more localised and/or specific to interactions with inter-
acting proteins. It is hoped that the overproduction and
purification of recombinant AIPL1 will facilitate further
structural studies via protein crystallisation, thereby
providing greater insights into the structure/function of
AIPL1.
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